High-Risk Cancer Clinical Trial
— CLUBNETOfficial title:
Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy
This study is aimed at evaluating the efficacy regarding the response rate and metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with high risk prostate cancer.
Status | Terminated |
Enrollment | 11 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Surgically resectable high risk prostate cancer with a 5-year relapse probability = 60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010) - no prior therapy for prostate cancer such as androgen deprivation therapy, radiation therapy, or chemotherapy - ECOG performance status 0-1 - No evidence of active infection - Hemoglobin >9.0 g/dL - Absolute neutrophil count >1.5 x 109/L, - Platelet count >100 x 109/L, - AST/SGOT and/or ALT/SGPT <2.5 x ULN; - Total bilirubin <1.0 x ULN, - Serum creatinine <1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded) - Patient information and signature of informed consent - Male = 18 years - Patients of reproductive age must take appropriate contraceptive precautions during and for 6 months after the end of their participation in the study Exclusion Criteria: - Evidence of lymph node, visceral or bone metastases - previous major intrapelvic surgery - previous radiation therapy to the small pelvis - any type of malignancies within the last 5 years except basalioma and non-muscle invasive urothelial cancer of the urinary bladder - previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any indication - Hypersensitivity to the active substance or to any of the excipients - Known or suspected brain metastases or leptomeningeal metastases - Active or symptomatic viral hepatitis or chronic liver disease - Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Uniklinik RWTH Aachen | Aachen | Nordrhein-Westfalen |
Lead Sponsor | Collaborator |
---|---|
RWTH Aachen University |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete pathological response rate | Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement. Key-parameters: Complete pathohistological remission Intra/perioperative compl. PFS Metastasis-FS Biochemical, radiological, clinical PFS and androgen-deprivation FS Objective progr. during cabazitaxel therapy (cab.th.) and post surgery PSA response at the end of cab.th. PSA progression after 12 w. of cab.th. Percentage of pat. with undetectable PSA (<0.1 ng/ml) post surgery Relationship between PSA kinetics, histol. response and MRI response Role of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response Immunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I & II, p53, bcl-2, Measurement of the serum concentrations of free circulating mDNA |
5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT03978663 -
Three Fraction Radiation to Induce Immuno-Oncologic Response
|
N/A | |
Withdrawn |
NCT05120622 -
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05254899 -
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
|
Phase 2 | |
Recruiting |
NCT04947098 -
Prevent Cancer- Greenville
|
||
Recruiting |
NCT06020443 -
Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France.
|
N/A | |
Completed |
NCT02308280 -
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT06046625 -
Needs and Preferences of Patients With Head-neck Cutaneous SCC
|
||
Recruiting |
NCT06277050 -
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT03343249 -
Adjunctive Smart Phone Based Smoking Cessation Treatment
|
N/A | |
Recruiting |
NCT06327568 -
Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
|
||
Recruiting |
NCT04334993 -
Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
|
Phase 2 | |
Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
Recruiting |
NCT05498272 -
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
|
Phase 2 | |
Terminated |
NCT01479192 -
Fenretinide in Healthy Young Women at Genetic and Familial Risk
|
Phase 3 | |
Recruiting |
NCT05557487 -
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
|
||
Recruiting |
NCT04217356 -
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
|
||
Recruiting |
NCT04740866 -
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
|
N/A | |
Recruiting |
NCT04905329 -
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
|
||
Active, not recruiting |
NCT01827137 -
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
|
N/A |